CatalystFDA/Bio

REVOLUTION MEDICINES, INC. (RVMD) DISCUSSES FDA APPROVAL OF RASONQUE FOR METASTATIC PANCREATIC CANCER AND IMPLICATIONS FOR RAS-DRIVEN THERAPY TRANSCRIPT - SEEKINGALPHA

FDA approval of Rasonque for metastatic pancreatic cancer marks a pivotal catalyst for RAS-driven therapy.

What changed

FDA approval of Rasonque for metastatic pancreatic cancer marks a pivotal catalyst for RAS-driven therapy.

Why it matters

FDA approval of Rasonque for metastatic pancreatic cancer marks a pivotal catalyst for RAS-driven therapy. — impact context not separately stored; see What changed.

Sources

seekingalpha